VANI

Vivani Medical, Inc.

1.51 USD

Last updated Sep 4, 21:00 UTC

Yesterday HIGH

$1.45

Yesterday LOW

$1.37

52w HIGH

$1.92

52w LOW

$0.92

EPS

-0.07

PE

-21.50

Next Earnings

Nov 12, 2026

Overview News Government Trades Fundamentals

Vivani Medical, Inc. stock is up 9.06% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 September’s closed higher than August.

Benzinga Newsdesk

Thu Aug 13, 2026

Vivani Medical Q2 EPS $(0.07) Beats $(0.08) Estimate

Vivani Medical (NASDAQ:VANI) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from
Benzinga Newsdesk

Tue Jul 7, 2026

Vivani Medical To Allow Novo Nordisk To Evaluate NPM-139, The Company’s Semaglutide Drug Implant

NPM-139, which utilizes Vivani’s NanoPortal™ platform technology, is under development for chronic weight management. There are no exclusivity provisions for NPM-139, or Vivani’s proprietary NanoPortal technology
Benzinga Newsdesk

Thu Jul 2, 2026

ClearOne To Acquire Vivani Medical Subsidiary Cortigent For 12.5M Shares Of CLRO Worth ~$40.4M; ClearOne To File S-1 Seeking To Raise $10M-$15M

Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that it has entered into a definitive agreement
Benzinga Newsdesk

Thu Jun 25, 2026

Vivani Medical Receives Approval From Australian Human Research Ethics Committee Bellberry To Initiate SLIM-1, A Phase 1 Clinical Trial Of Semaglutide Implant NPM-139

Vivani CEO Adam Mendelsohn, Ph.D., stated, "HREC approval to initiate SLIM-1 in Australia marks an important moment for our Company, clearing the way for near-term, mid-2026, initiation. We are eager to conduct this
Benzinga Newsdesk

Tue Jun 23, 2026

Lake Street Initiates Coverage On Vivani Medical with Buy Rating, Announces Price Target of $4

Lake Street analyst Thomas Flaten initiates coverage on Vivani Medical (NASDAQ:VANI) with a Buy rating and announces Price Target of $4.
Benzinga Insights

Thu Apr 16, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session